mProX™ Human CD47 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Immune Checkpoint Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human CD47 Stable Cell Line (S01YF-1023-PY176). Click the button above to contact us or submit your feedback about this product.
Cameron Garcia (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Morgan Smith (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Silencing CD47 enhances phagocytic activity in vitro while suppressing tumor development in vivo using the SK-OV-3 ovarian cancer cell line.
The quantification of tumor quantities in mice engrafted with SK-OV-3 cells that underwent shCD47 or scramble shRNA transfection was assessed using an Unpaired Student's-t test with a two-tailed analysis, revealing a statistically significant difference (*p < 0.05). Additionally, Kaplan-Meier plots demonstrated improved overall survival rates in mice engrafted with CD47 knockdown SK-OV-3 cells (N=6), as determined by a Log-rank test, showing strong significance (**p < 0.01).
Ref: Liu, Ran, et al. "CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis." Oncotarget 8.24 (2017): 39021.
Pubmed: 28380460
DOI: 10.18632/oncotarget.16547
Research Highlights
Luo, Wen. et al. "A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma." Frontiers in immunology, 2023.
The recent advancements in cancer immunotherapy have sparked a revolution in cancer treatment. However, the evaluation of these therapies has been hindered by the lack of functional human immune systems in current small animal models, which are mostly syngeneic, genetically engineered, or immunodeficient mouse models. Additionally, developing animal models for bone cancer faces another hurdle regarding the engraftment sites for tumors. To overcome this challenge, a protocol has been developed for an orthotopic humanized mouse model of Ewing sarcoma, a bone and soft tissue sarcoma, by transplanting fresh human cord blood CD34+ cells.
Luo, Wen. et al. "A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma." Frontiers in immunology, 2023.
Pubmed:
37868989
DOI:
10.3389/fimmu.2023.1277987
Pla-López, Alberto, et al. "Aryl Azoles Based Scaffolds for Disrupting Tumor Microenvironment." Bioorganic & Medicinal Chemistry (2023): 117490.
Thirty-nine aryl azoles, thirteen triazoles and twenty-seven tetrazoles were synthesized and biologically tested to assess their potential as tumor microenvironment disruptors. The compounds were evaluated for their antiproliferative activity on HT-29, A-549 and MCF-7 tumor cell lines, as well as on the non-tumor cell line HEK-293. In HT-29 cells, the expression levels of PD-L1, CD-47, c-Myc and VEGFR-2 were also studied, as these are involved in tumor microenvironment processes. Furthermore, the compounds were evaluated for their antiproliferative activity when co-cultured with THP-1 monocytes and their ability to affect IL-6 secretion. The effect of selected compounds on angiogenesis in HMEC-1 and on vasculogenic mimicry on HEK-293 was also assessed. Notably, compounds with an amino group in the phenyl ring and a halogen atom in the benzyl ring showed promising results as tumor microenvironment disruptors. The most notable compound showed a significant decrease in the population of HT-29 cells when co-cultured with THP-1 monocytes, as well as a moderate effect on PD-L1, CD-47 and c-Myc expression.
Pla-López, Alberto, et al. "Aryl Azoles Based Scaffolds for Disrupting Tumor Microenvironment." Bioorganic & Medicinal Chemistry (2023): 117490.
Pubmed:
37862936
DOI:
10.1016/j.bmc.2023.117490
